Adult Lamivudine and Tenofovir Biocomparison Study for Pediatric Fixed Dose Combination Formulation

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-004392-41

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the comparative bioavailability of: 1.lamivudine 300mg: a. adult marketed tablets to the investigational oral pediatric uncoated/coated granules-fasted conditions b.investigational oral pediatric uncoated granules-fasted conditions, to the investigational oral pediatric uncoated granules-fasted conditions+vanilla pudding/applesauce c.investigational oral pediatric coated granules-fasted conditions, to the investigational oral pediatric coated granules-fasted conditions+vanilla pudding/applesauce 2.tenofovir 300mg: a.adult marketed tablets to the investigational oral pediatric uncoated/coated granules - under fasted conditions b.investigational oral pediatric uncoated granules-fasted conditions, to the investigational oral pediatric uncoated granules-fasted conditions+vanilla pudding/applesauce c.investigational oral pediatric coated granules-fasted conditions, to the investigational oral pediatric coated granules - fasted conditions+vanilla pudding/applesauce


Critère d'inclusion

  • HIV-1 infection

Liens